. 2018 Jun;10(6):a030700. doi: 10.1101/cshperspect.a030700

Table 2.

Year 2 chimeric-yellow fever-dengue (CYD) vaccine protective efficacy in an intention-to-treat (postdose 1) analysis in persons who prior to vaccination were seronegative or seropositive for dengue virus (DENV), Japanese encephalitis (JE) antibodies (Southeast Asia), or DENV antibodies (Americas)

	Seronegatives			Seropositives
Clinical study	Cases/person years		Vaccine efficacy (%) CI	Cases/person years		Vaccine efficacy (%) CI
Clinical study	Vaccine	Control	Vaccine efficacy (%) CI	Vaccine	Control	Vaccine efficacy (%) CI
Southeast Asia	23/424	18/216	34.9% (−18.0–64.1) p = 0.16	18/901	34/444	73.9% (54.3–86.3) p = <0.001
Americas	9/258	9/149	42.2% (−42.3–76.6) p = 0.24	8/1073	23/512	83.4% (63.2–92.5) p = <0.001
Combined	32/682	27/365	36.6% (−4.2–61.4) p = 0.08	26/1974	57/956	77.9% (65.1–86.0) p = <0.001

Data combined with that from supplemental Figure S6 in Hadinegoro et al. (2015).